ArticleFrontiers in immunology2026
Developing a new assessment model for systemic lupus erythematosus disease activity based on a case cohort.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a novel SLE disease activity scoring model designed to enhance diagnostic capability for moderate-to-severe disease activity in SLE patients compared to the SLE Disease Activity Index 2000 (SLEDAI-2K). Methods: All 1163 SLE patients from Shandong Provincial Hospital and the Affiliated Hospital of Qingdao University constituted the derivation cohort, while another 323 patients from Shandong Provincial Hospital served as the validation cohort. Disease activity was assessed for each patient using the Physician Global Assessment (PGA) and SLEDAI-2K. With PGA-defined moderate-to-severe SLE activity as the dependent variable, binary logistic regression analysis identified factors influencing disease activity and constructed a regression model. Receiver operating characteristic (ROC) curve analysis evaluated the model's discriminative ability. Correlations between the new scoring model, PGA, and SLEDAI-2K were examined. Results: Binary logistic regression identified 25 clinical manifestations as independent risk factors for higher SLE activity (all P<0.05): neuropsychiatric symptoms, visual impairment, vasculitis, arthritis, myositis, hematuria, proteinuria, pyuria, alopecia, rash, mucosal ulcers, pleurisy, pericarditis, hypocomplementemia, elevated anti-dsDNA, fever, thrombocytopenia, leukopenia, pulmonary hypertension, hypothyroidism, hypocalcemia, lymphadenopathy, abnormal liver function, high-titer ANUA. Using the 25 variables listed above, we constructed a new scoring model. ROC analysis for distinguishing moderate-to-severe activity showed areas under the curve of 0.972 (95% CI: 0.963-0.980, P<0.001) in the derivation cohort and 0.971 (95% CI: 0.958-0.985, P<0.001) in the validation cohort. Conclusion: Twenty-five clinical manifestations were identified as independent risk factors for assessing moderate-to-severe SLE activity. The resulting model demonstrated enhanced accuracy in identifying moderate-to-severe disease activity states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.